110 related articles for article (PubMed ID: 18762159)
1. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
[TBL] [Abstract][Full Text] [Related]
2. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
6. Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors.
Yamamoto N; Hasegawa H; Seki H; Ziegelbauer K; Yasuda T
Anal Biochem; 2003 Apr; 315(2):256-61. PubMed ID: 12689835
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
8. Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.
Singh D; Rani R; Rajendran R; Kaur NJ; Pandey A; Chopra P; Jain T; Jain MK; Grover S; Arya R; Saini KS
Biotechnol J; 2010 Feb; 5(2):201-12. PubMed ID: 20013945
[TBL] [Abstract][Full Text] [Related]
9. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
12. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
[TBL] [Abstract][Full Text] [Related]
13. Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
Rossi AB; Herlaar E; Braselmann S; Huynh S; Taylor V; Frances R; Issakani SD; Argade A; Singh R; Payan DG; Masuda ES
J Allergy Clin Immunol; 2006 Sep; 118(3):749-55. PubMed ID: 16950297
[TBL] [Abstract][Full Text] [Related]
14. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
15. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
16. SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
18. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
19. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
20. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]